JinMatrix Files International Patent for Cervical Cancer Treatment Candidate 'GMT-PC02'

[Asia Economy Reporter Lee Gwan-joo] JinMatrix announced on the 18th that it has filed an international patent for its cervical cancer treatment candidate substance, ‘GMT-PC02’.

GMT-PC02 is designed with the E6 and E7 oncogenic proteins of human papillomavirus types 16 and 18 (HPV16, HPV18), known as the causative viruses of cervical cancer, as immune antigens. It was developed to induce a T-cell immune response specific to these tumor antigens upon administration, and its efficacy was evaluated using a cervical cancer animal test model developed by Johns Hopkins University in the United States.

JinMatrix explained that in animal tests, when GMT-PC02 was administered to mice with growing cervical cancer tumor cells, tumor cell growth was suppressed by more than 80% compared to the control group. Additionally, when GMT-PC02 was pre-administered to normal mice followed by cancer cell challenge vaccination, a 100% cancer prevention effect was observed, with no cervical cancer tissue detected.

Based on the animal test results, JinMatrix filed this international patent. A JinMatrix official stated, “Since we have confirmed both the tumor suppression effect and preventive effect of the immuno-oncology candidate ‘GMT-PC02,’ developed based on our proprietary gene delivery technology, the company plans to actively pursue clinical development of the cervical cancer treatment in the future.”